NDATOPICALCREAM
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
SOOLANTRA (ivermectin) by Galderma is 12. First approved in 2014.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOOLANTRA (ivermectin 1% cream) is a topical antiparasitic agent approved for rosacea, though its exact mechanism of action in treating rosacea lesions remains unknown. It is absorbed systemically with peak plasma concentrations occurring 10 hours post-dose and has a terminal half-life of approximately 6.5 days with no accumulation over 52 weeks of use.
$0.002BPart D
Peak7.7 years to LOESOOLANTRA is at peak lifecycle with modest Medicare spending, indicating an established but niche dermatology franchise requiring specialized commercial teams.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of ivermectin cream in treating rosacea lesions is unknown. 12.2 Pharmacodynamics Cardiac Electrophysiology At therapeutic doses, ivermectin cream is not expected to prolong QTc interval. 12.3 Pharmacokinetics Absorption The absorption of ivermectin…
Pharmacologic Class:
Antiparasitic
Indications
Worked on SOOLANTRA at Galderma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.